China Biologic Products Inc., of Beijing, said it received the good manufacturing practice certification from the CFDA for its plasma production facility at its Guizhou subsidiary. That will allow the firm to resume full-scale commercial production later this month for all of its approved plasma products, including the newly approved human prothrombin complex concentrate.